 | • レポートコード：MRC2305C044 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、229ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界の直接作用型抗ウイルス薬（DAA）市場規模が2021年に8,239.12百万ドル、2022年に9,411.00百万ドルとなり、更に年平均13.70％成長して2027年には17,802.52百万ドルに達すると予測しています。当市場調査レポートでは、直接作用型抗ウイルス薬（DAA）の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別分析（NS3/4Aプロテアーゼ、NS5Aタンパク質、NS5BRNA依存性RNAポリメラーゼ）、疾患別分析（HIV感染症/エイズ、C型肝炎ウイルス、インフルエンザ、予防）、ルート別分析（静脈内投与、経口投与、皮下投与、局所投与）、流通チャネル別分析（病院薬局、オンライン薬局、小売薬局）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、当書には、A-S Medication Solutions、Actavis Group Ptc Ehf.、Agouron Pharmaceuticals、Aizant Drug Research Solutions Pvt Ltd、Amneal Pharmaceuticals LLC、Apotex Corporation、Atea Pharmaceuticals, Inc.、Auro Pharma Inc、Boehringer Ingelheim Pharmaceuticals Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の直接作用型抗ウイルス薬（DAA）市場規模：種類別 - NS3/4Aプロテアーゼの市場規模 - NS5Aタンパク質の市場規模 - NS5BRNA依存性RNAポリメラーゼの市場規模 ・世界の直接作用型抗ウイルス薬（DAA）市場規模：疾患別 - HIV感染症/エイズにおける市場規模 - C型肝炎ウイルスにおける市場規模 - インフルエンザにおける市場規模 - 予防における市場規模 ・世界の直接作用型抗ウイルス薬（DAA）市場規模：ルート別 - 静脈内投与の市場規模 - 経口投与の市場規模 - 皮下投与の市場規模 - 局所投与の市場規模 ・世界の直接作用型抗ウイルス薬（DAA）市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の直接作用型抗ウイルス薬（DAA）市場規模：地域別 - 南北アメリカの直接作用型抗ウイルス薬（DAA）市場規模 アメリカの直接作用型抗ウイルス薬（DAA）市場規模 カナダの直接作用型抗ウイルス薬（DAA）市場規模 ブラジルの直接作用型抗ウイルス薬（DAA）市場規模 ... - アジア太平洋の直接作用型抗ウイルス薬（DAA）市場規模 日本の直接作用型抗ウイルス薬（DAA）市場規模 中国の直接作用型抗ウイルス薬（DAA）市場規模 インドの直接作用型抗ウイルス薬（DAA）市場規模 韓国の直接作用型抗ウイルス薬（DAA）市場規模 台湾の直接作用型抗ウイルス薬（DAA）市場規模 ... - ヨーロッパ/中東/アフリカの直接作用型抗ウイルス薬（DAA）市場規模 イギリスの直接作用型抗ウイルス薬（DAA）市場規模 ドイツの直接作用型抗ウイルス薬（DAA）市場規模 フランスの直接作用型抗ウイルス薬（DAA）市場規模 ロシアの直接作用型抗ウイルス薬（DAA）市場規模 ... - その他地域の直接作用型抗ウイルス薬（DAA）市場規模 ・競争状況 ・企業情報 |
The Global Direct-acting Antiviral Drug Market size was estimated at USD 8,239.12 million in 2021 and expected to reach USD 9,411.00 million in 2022, and is projected to grow at a CAGR 13.70% to reach USD 17,802.52 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Direct-acting Antiviral Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase.
Based on Indication, the market was studied across HIV Infection/ AIDS, Hepatitis C Virus, Influenza, and Prophylaxis.
Based on Route, the market was studied across Intravenous, Oral, Subcutaneous, and Topical.
Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Drug Store, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Direct-acting Antiviral Drug market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Direct-acting Antiviral Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Direct-acting Antiviral Drug Market, including A-S Medication Solutions, Actavis Group Ptc Ehf., Agouron Pharmaceuticals, Aizant Drug Research Solutions Pvt Ltd, Amneal Pharmaceuticals LLC, Apotex Corporation, Atea Pharmaceuticals, Inc., Auro Pharma Inc, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, Camber Pharmaceuticals, Inc., Cipla USA Inc., E.R. Squibb & Sons, L.L.C., F. Hoffmann-La Roche, Genentech, Inc., H.J. Harkins Company, Jamp Pharma Corporation, Marcan Pharmaceuticals Inc, Merck Ltd., Mylan N.V., New American Therapeutics, Inc, Novartis, PD-Rx Pharmaceuticals, Inc., Pfizer Inc., Physicians Total Care, Inc., Prestium Pharma, Inc., Remedy Repack, Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Direct-acting Antiviral Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Direct-acting Antiviral Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Direct-acting Antiviral Drug Market?
4. What is the competitive strategic window for opportunities in the Global Direct-acting Antiviral Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Direct-acting Antiviral Drug Market?
6. What is the market share of the leading vendors in the Global Direct-acting Antiviral Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Direct-acting Antiviral Drug Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
5.1.1.2. Increasing product development and launch of new direct-acting antiviral medicines
5.1.1.3. Growing awareness and improving healthcare outlook in emerging countries
5.1.2. Restraints
5.1.2.1. Difficulties in obtaining insurance approval for new HCV treatment regimens
5.1.2.2. High cost of drugs
5.1.3. Opportunities
5.1.3.1. Increasing support from government authorities & social healthcare associations
5.1.3.2. Availability of directly-acting antivirals medicines and strategic collaborations
5.1.4. Challenges
5.1.4.1. Patent expiration of branded direct-acting antiviral
5.1.4.2. unmeasured side effects associated with the Direct-Acting Antiviral drugs
5.2. Cumulative Impact of COVID-19
6. Direct-acting Antiviral Drug Market, by Type
6.1. Introduction
6.2. NS3/4A Protease
6.3. NS5A Protein
6.4. NS5B RNA-Dependent RNA polymerase
7. Direct-acting Antiviral Drug Market, by Indication
7.1. Introduction
7.2. HIV Infection/ AIDS
7.3. Hepatitis C Virus
7.4. Influenza
7.5. Prophylaxis
8. Direct-acting Antiviral Drug Market, by Route
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
8.5. Topical
9. Direct-acting Antiviral Drug Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Drug Store
9.4. Retail Pharmacy
10. Americas Direct-acting Antiviral Drug Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Direct-acting Antiviral Drug Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Direct-acting Antiviral Drug Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. A-S Medication Solutions
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Actavis Group Ptc Ehf.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Agouron Pharmaceuticals
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Aizant Drug Research Solutions Pvt Ltd
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Amneal Pharmaceuticals LLC
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Apotex Corporation
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Atea Pharmaceuticals, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Auro Pharma Inc
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Boehringer Ingelheim Pharmaceuticals Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Bristol-Myers Squibb Company
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Camber Pharmaceuticals, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Cipla USA Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. E.R. Squibb & Sons, L.L.C.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. F. Hoffmann-La Roche
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Genentech, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. H.J. Harkins Company
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Jamp Pharma Corporation
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Marcan Pharmaceuticals Inc
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Merck Ltd.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Mylan N.V.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. New American Therapeutics, Inc
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Novartis
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. PD-Rx Pharmaceuticals, Inc.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Pfizer Inc.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Physicians Total Care, Inc.
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. Prestium Pharma, Inc.
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
14.27. Remedy Repack
14.27.1. Business Overview
14.27.2. Key Executives
14.27.3. Product & Services
14.28. Sciegen Pharmaceuticals Inc.
14.28.1. Business Overview
14.28.2. Key Executives
14.28.3. Product & Services
14.29. Teva Pharmaceuticals USA, Inc.
14.29.1. Business Overview
14.29.2. Key Executives
14.29.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing